cincorlogo.jpg
CinCor Pharma Appoints Terry Coelho as Executive Vice President, Chief Financial Officer and Chief Business Development Officer
28 oct. 2021 08h00 HE | CinCor Pharma, Inc.
CINCINNATI, Oct. 28, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Terry Coelho as Executive Vice President, Chief Financial Officer and Chief Business...
cincorlogo.jpg
CinCor Pharma Appoints Mason Freeman, M.D., as Executive VP, Clinical Development
19 oct. 2021 08h00 HE | CinCor Pharma, Inc.
CINCINNATI, Oct. 19, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Mason W. Freeman, M.D., as Executive Vice President, Clinical Development responsible...
cincorlogo.jpg
CinCor Pharma Raises $143 Million in Series B Financing
12 oct. 2021 08h00 HE | CinCor Pharma, Inc.
Funding will support continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate, for the treatment of hypertension, primary...
cincorlogo.jpg
CinCor Pharma Appoints Marc de Garidel as Chief Executive Officer
06 juil. 2021 08h00 HE | CinCor Pharma, Inc.
CINCINNATI, July 06, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Marc de Garidel, currently on the Company’s Board of Directors, as Chief Executive...
cincorlogo.jpg
CinCor Pharma Announces Appointments of Three Experienced Independent Members to Its Board of Directors
20 mai 2021 08h00 HE | CinCor Pharma, Inc.
Experienced biopharmaceutical executive, John F. Thero, Chief Executive Officer of Amarin Corporation PLC, a commercial-stage cardiovascular companySeasoned biopharmaceutical finance executive, Troy...
cincorlogo.jpg
CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects
20 oct. 2020 08h00 HE | CinCor Pharma, Inc.
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that...
CinCor Pharma In-Licenses Aldosterone Synthase Inhibitor, CIN-107, and Closes $50 Million Series A Financing
14 mai 2019 08h00 HE | CinCor Pharma, Inc.
CINCINNATI, May 14, 2019 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced today that it has signed an agreement with Roche to acquire exclusive global rights to a novel aldosterone...